Product Code: RP-ID-10325828 |
Published Date: 21 Oct 2022 |
Region: NA |
Category: Healthcare & Pharmaceuticals |
Report ID: 10325828
Market Overview:
Nebulizers and Inhalers Market (Nebulizers (Ultrasonic Nebulizers [Pneumatic {Breath-Enhanced and Breath-Actuated}, Mesh Nebulizers [Active Mesh Nebulizers and Passive Mesh Nebulizers]) and Inhalers (Dry Powder Inhaler and Meter Dose Inhaler), End-users (Hospitals, Ambulatory Care Centers, and Home Care), and Regions (North America, Europe, Asia Pacific, and Rest of the World) - Global Forecast up to 2025
Global Neurostimulation Devices Market By Product Type (SCS, DBS, SNS, VNS,
and GES), By Applications Type (Pain Management, Urinary & Fecal Incontinence,
and Epilepsy), By End-users (Hospitals and Trauma Centers), and By Regions
(North America, Europe, APAC, and RoW) – Forecast up to 2025
This market research report includes a detailed segmentation of the global
neurostimulation devices market by product type (SCS, DBS, SNS, VNS, and GES), by
applications type (pain management, urinary & fecal incontinence, and epilepsy), by
end-users (hospitals and trauma centers), and by regions (North America, Europe,
APAC, and RoW).
Research Overview
Infoholic Research predicts that the global neurostimulation devices market will grow at a CAGR
of 12.18% during the forecast period 2019–2025. Neurostimulation devices are designed
specifically to treat various conditions effectively by delivering low voltage electricity to specific
parts of the patient brain, spinal cord, or peripheral nervous system. Several kinds of research
have revealed that neurostimulation therapy has improved the ability to function and participate
in activities of daily living. Thus, neurostimulation devices are found to be effective among
patients suffering from various neurological disorders, thereby influencing the growth of the
global neurostimulation devices market. The drug-free advantages of neurostimulation devices
in chronic pain management without opioids can be a lifesaver for many as it avoids the
systemic impacts and possible addictive outcomes of drug therapy. Their promising results in
improving the quality of life have enabled many healthcare providers and facilities to deliver
rapid, safe, and effective treatment procedures.
Recent advancements in neurotechnology and neuroimaging, along with an increased
understanding of neurocircuitry, are providing the necessary tools to treat patients with many
debilitating neurologic and psychiatric disorders that are contributing to the rapid rise in the use
of neurostimulation therapies. After remaining relatively stagnant for the past 30 years, electrical
stimulation technologies are evolving toward potential closed-loop therapeutic control systems
with the ability to deliver stimulation with a higher spatial resolution to provide continuously
customized neuromodulation for optimal clinical outcomes. Also, advancements such as
electrode design to enable long-term high-precision sensing and stimulating as well as
computing approaches to acquire and assess meaningful feedback signals in real-time to adapt
stimulation parameters accordingly are boosting the neurostimulation devices market. With the
advent of new technologies-enabled devices, manufacturers have focused on developing tools
and devices that transform disease treatment on a global scale to be less toxic, less invasive, and
more effective, using precise ultra-low radiofrequency energy. Such promising results of
neurostimulation devices are making manufacturers invest more in R&D for the development of
advanced products. Hence there would be a growing demand for the development of effective
neurovascular devices and commercialization during the forecast period.
•TheintroductionofsmartneurostimulationdevicehasledtothehigheradaptationrateinallhealthcaresystemmakingkeyplayersinvestmoreonR&Dtobringmoreadvanceddevicesintothemarket.•Intheelderlypopulation,minimallyinvasiveneuromodulationsurgeriesarewidelypreferredtoovercomemajorpost-surgerycomplications.Opportunities
Risk•Paucityofskilleddoctorsandrisksassociatedwithneurostimulationprocedureswillrestrainthemarketgrowth.•Availabilityofalternativetherapeuticproceduresandstringentregulatoryframeworkarethemajorfactorshamperingthemarketgrowth.
Drivers•Increaseintheprevalenceofneurologicaldiseaseiscreatingthethedemandforneurostimulationdevices.•Agingpopulationwhoareatriskofdevelopingneurologicaldisordersmayresultinincreasedhealthcareexpenditure.
Market dynamics
•Theintroductionofadvanceneurostimulationdeviceshasledtohigheradoptionandacceptanceinallhealthcaresystems.•Advancedfeaturesandminimalinvasivenaturehaveminimizedthecomplicationsandimprovedpatienthealthoutcomes&safety.•Self-managementbyhandheldmedicaldevicesthatenablespatientstoself-administerdiscretedosesofnon-invasivenervestimulationhasincreasedamongseveralpatients.CAGR of 12.18%: 2019–2025
CAGR: 17.56%
North America is considered as the largest region in the global neurostimulation devices market
due to extensive technological advancements, sophisticated healthcare infrastructures, and
various government initiatives in the region. Europe was observed to be the second-largest
region in the neurostimulation devices market owing to the presence of a large number of
manufacturers in the region. The major factor driving the market in Asia Pacific includes the
acceptance and demand for high-end medical infrastructure in the region. China, Japan, and
India are expected to grow at a faster rate when compared to other countries in the Asia Pacific
region.
Segmentation by Product Type:
ï‚· SCS System
ï‚· DBS System
ï‚· SNS System
ï‚· VNS System
ï‚· GES System
The spinal cord stimulator (SCS) system accounted for the largest revenue-generating segment
due to the large population base suffering from chronic pain, following major surgeries and
spinal cord injuries.
Segmentation by Application Type:
ï‚· Pain Management
ï‚· Urinary & Fecal Incontinence
ï‚· Epilepsy
The pain management segment was leading with the largest revenue owing to the higher
adaptation of these devices to manage chronic pain in all age groups.
Segmentation by End-users:
ï‚· Hospitals
ï‚· Trauma Centers
In 2018, the hospital segment was leading with maximum revenue in the global
neurostimulation devices market with a large number of users and patients globally.
Segmentation by Region:
ï‚· North America
ï‚· Europe
ï‚· APAC
ï‚· RoW
The regions covered in the report include North America, Europe, Asia Pacific, and Rest of the
World. North America is set to be the leading region in the global neurostimulation devices
market, followed by Europe. Asia Pacific and RoW are set to be the emerging regions. The
emerging markets have a high potential to grow owing to an increase in the patient population
and focus on various chronic disorders. The global neurostimulation devices market is likely to
seek a steady penetration rate in the emerging market, and most of the vendors are targeting to
penetrate India, China, and Japan markets. Further, factors such as large patient population and
government initiatives have become a new trend in the emerging markets.
Competitive Analysis – The vendors have a strong focus on introducing technologically
advanced cost-effective devices with long battery, improved efficiency, safety, user-friendliness,
and miniaturization to improve patients' experience and clinical outcomes, which are making
global neurostimulation devices market a highly competitive market. Growing demand for the
detection of illnesses, including gastroparesis, Parkinson's disease, dystonia, and depression, are
providing tremendous opportunities for players to come up with product enhancements and
leverage their product portfolio globally. This may further heat the competition among existing
vendors leading to the development of products in less time and fasten the regulation process
with effective means to commercialize the product early into the market to stay dominant.
Favorable government policies are also making way for other small companies to enter the
market, which are striving to develop simulators.
Key Vendors:
ï‚· Medtronic plc
ï‚· Abbott Laboratories
ï‚· Boston Scientific Corporation
ï‚· Cyberonics, Inc. (LivaNova, PLC)
Key Competitive Facts:
ï‚· The market is highly competitive, with all the players competing to gain the market share.
Intense competition, rapid advancements in technology, frequent changes in
government policies, and price are key factors that confront the market.
ï‚· The requirement of high initial investment, implementation, and stringent regulatory
framework in the market are also limiting the entry of new players.
ï‚· Responding to competitive pricing pressures specific to each of the geographic markets.
ï‚· Protection of proprietary technology for products and manufacturing processes.
Benefits – The report provides complete details about the importance and adoption rate of
neurostimulation devices. Thus, the key stakeholders can know about the major trends, drivers,
investments, vertical player’s initiatives, and government initiatives toward the medical devices
segment in the upcoming years along with details of the pureplay companies entering the
market. Moreover, the report provides details about the major challenges that are going to
impact the market growth. Additionally, the report gives complete details about the key business
opportunities to stakeholders in order to expand their business and capture the revenue in
specific verticals and to analyze before investing or expanding the business in this market.
Key Takeaways:
ï‚· Understanding the potential market opportunity with precise market size and forecast
data.
ï‚· Detailed market analysis focusing on the growth of the neurostimulation devices market
globally.
ï‚· Factors influencing the growth of the neurostimulation devices market.
ï‚· In-depth competitive analysis of dominant and pureplay vendors.
ï‚· Prediction analysis of the neurostimulation products industry across the globe.
ï‚· Key insights related to major segments of the neurostimulation devices market globally.
ï‚· The latest market trend analysis impacting the buying behavior of the consumers.
Medtronic plc
Becton and Dickinson Company
GSK plc
AstraZeneca plc
Boehringer-Ingelheim
3M
OMRON Corp.
PARI Medical Holdings GmbH
Philips Healthcare
Related Reports
Proof of Quality & Reliability
